Role of a Disease-associated ST3Gal-4 in Non-small Cell Lung Cancer

Singh, Prince Kumar; Joon, Archana; Kumari, Munmun; Singh, Tanya; Bal, Amanjit; Maan, Pratibha; Ghosh, Sujata

doi:10.1007/s12013-022-01091-3

Cited by 3 publications

(4 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ST6GAL1 may be involved in cell invasion and tumorigenesis of NSCLC via Notch1/Hes1/MMP signaling ( 80 ). ST3GAL4 may regulate the proliferation, invasion, and migration of NSCLC cells through α-2,3 sialylation of HSP60 ( 82 ). ST3GAL6 expression is downregulated in LUAD, which results in poor prognosis ( 79 ).…”

Section: Glycoenzyme-based Protein Glycosylation Changes In Crdsmentioning

confidence: 99%

“…Munkley J. reviewed the inhibitors of STs, including ST3GAL1, ST3GAL3, ST6GAL1, ST6GalNAc2, and ST8SIA3 ( 140 ). Increased expressions of ST3GAL4 ( 82 ), ST6GAL1 ( 80 ), and ST6GalNAc1 ( 81 ) were identified in most patients with NSCLC, and inhibiting these enzymes may suppress NSCLC cell metastasis. Further research is required to map the expression of all STs in various lung cancers, and the use of different ST inhibitors in combination therapy may be a new promising cancer therapy.…”

Section: Clinical Potential In Therapeutic Applicationsmentioning

confidence: 99%

“…Membrane proteins Elevated ST3GAL4 and sialylation of membrane proteins contribute to the activation of E-cadherin/ b-catenin, AKT, and ERK/NF-kB mediated signal transduction pathways (82). NEU1 / NEU1 is correlated with the severity of drug resistance in DLKP, a lung cancer model with a series of drug-resistant variants (83).…”

Section: St3gal4mentioning

confidence: 99%

See 2 more Smart Citations

Targeting protein glycosylation to regulate inflammation in the respiratory tract: novel diagnostic and therapeutic candidates for chronic respiratory diseases

2023

View full text Add to dashboard Cite

Protein glycosylation is a widespread posttranslational modification that can impact the function of proteins. Dysregulated protein glycosylation has been linked to several diseases, including chronic respiratory diseases (CRDs). CRDs pose a significant public health threat globally, affecting the airways and other lung structures. Emerging researches suggest that glycosylation plays a significant role in regulating inflammation associated with CRDs. This review offers an overview of the abnormal glycoenzyme activity and corresponding glycosylation changes involved in various CRDs, including chronic obstructive pulmonary disease, asthma, cystic fibrosis, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, non-cystic fibrosis bronchiectasis, and lung cancer. Additionally, this review summarizes recent advances in glycomics and glycoproteomics-based protein glycosylation analysis of CRDs. The potential of glycoenzymes and glycoproteins for clinical use in the diagnosis and treatment of CRDs is also discussed.

show abstract

Section: Glycoenzyme-based Protein Glycosylation Changes In Crdsmentioning

confidence: 99%

Section: Clinical Potential In Therapeutic Applicationsmentioning

confidence: 99%

See 1 more Smart Citation

Targeting protein glycosylation to regulate inflammation in the respiratory tract: novel diagnostic and therapeutic candidates for chronic respiratory diseases

2023

View full text Add to dashboard Cite

show abstract

“…The process of cancer metastasis can be briefly summarized as cancer cells escaping their initial sites, surviving in blood and lymph transfer, and developing new distal tumor sites. Sialylation modifies the conformation of essential proteins to promote cancer cell proliferation, invasion, and migration [ 42 ]. α2-6-Sialylation of epidermal growth factor receptor (EGFR) regulates the epithelial-to-mesenchymal transition (EMT) of cancer cells [ 43 ] and sustains its membrane retention, regulating integrin tension, focal adhesion, and cell motility [ 44 , 45 ].…”

Section: Sialylation and Cancer Metastasismentioning

confidence: 99%

Insights into the Role of Sialylation in Cancer Metastasis, Immunity, and Therapeutic Opportunity

Huang

Zhang

2022

Cancers

View full text Add to dashboard Cite

Sialylation is an enzymatic process that covalently attaches sialic acids to glycoproteins and glycolipids and terminates them by creating sialic acid-containing glycans (sialoglycans). Sialoglycans, usually located in the outmost layers of cells, play crucial biological roles, notably in tumor transformation, growth, metastasis, and immune evasion. Thus, a deeper comprehension of sialylation in cancer will help to facilitate the development of innovative cancer therapies. Cancer sialylation-related articles have consistently increased over the last four years. The primary subjects of these studies are sialylation, cancer, immunotherapy, and metastasis. Tumor cells activate endothelial cells and metastasize to distant organs in part by the interactions of abnormally sialylated integrins with selectins. Furthermore, cancer sialylation masks tumor antigenic epitopes and induces an immunosuppressive environment, allowing cancer cells to escape immune monitoring. Cytotoxic T lymphocytes develop different recognition epitopes for glycosylated and nonglycosylated peptides. Therefore, targeting tumor-derived sialoglycans is a promising approach to cancer treatments for limiting the dissemination of tumor cells, revealing immunogenic tumor antigens, and boosting anti-cancer immunity. Exploring the exact tumor sialoglycans may facilitate the identification of new glycan targets, paving the way for the development of customized cancer treatments.

show abstract

Exploring the relationship between metabolism and immune microenvironment in osteosarcoma based on metabolic pathways

Wu,

Tan,

Shen

et al. 2024

J Biomed Sci

View full text Add to dashboard Cite

Background Metabolic remodeling and changes in tumor immune microenvironment (TIME) in osteosarcoma are important factors affecting prognosis and treatment. However, the relationship between metabolism and TIME needs to be further explored. Methods RNA-Seq data and clinical information of 84 patients with osteosarcoma from the TARGET database and an independent cohort from the GEO database were included in this study. The activity of seven metabolic super-pathways and immune infiltration levels were inferred in osteosarcoma patients. Metabolism-related genes (MRGs) were identified and different metabolic clusters and MRG-related gene clusters were identified using unsupervised clustering. Then the TIME differences between the different clusters were compared. In addition, an MRGs-based risk model was constructed and the role of a key risk gene, ST3GAL4, in osteosarcoma cells was explored using molecular biological experiments. Results This study revealed four key metabolic pathways in osteosarcoma, with vitamin and cofactor metabolism being the most relevant to prognosis and to TIME. Two metabolic pathway-related clusters (C1 and C2) were identified, with some differences in immune activating cell infiltration between the two clusters, and C2 was more likely to respond to two chemotherapeutic agents than C1. Three MRG-related gene clusters (GC1-3) were also identified, with significant differences in prognosis among the three clusters. GC2 and GC3 had higher immune cell infiltration than GC1. GC3 is most likely to respond to immune checkpoint blockade and to three commonly used clinical drugs. A metabolism-related risk model was developed and validated. The risk model has strong prognostic predictive power and the low-risk group has a higher level of immune infiltration than the high-risk group. Knockdown of ST3GAL4 significantly inhibited proliferation, migration, invasion and glycolysis of osteosarcoma cells and inhibited the M2 polarization of macrophages. Conclusion The metabolism of vitamins and cofactors is an important prognostic regulator of TIME in osteosarcoma, MRG-related gene clusters can well reflect changes in osteosarcoma TIME and predict chemotherapy and immunotherapy response. The metabolism-related risk model may serve as a useful prognostic predictor. ST3GAL4 plays a critical role in the progression, glycolysis, and TIME of osteosarcoma cells.

show abstract

Role of a Disease-associated ST3Gal-4 in Non-small Cell Lung Cancer

Cited by 3 publications

References 54 publications

Targeting protein glycosylation to regulate inflammation in the respiratory tract: novel diagnostic and therapeutic candidates for chronic respiratory diseases

Targeting protein glycosylation to regulate inflammation in the respiratory tract: novel diagnostic and therapeutic candidates for chronic respiratory diseases

Insights into the Role of Sialylation in Cancer Metastasis, Immunity, and Therapeutic Opportunity

Exploring the relationship between metabolism and immune microenvironment in osteosarcoma based on metabolic pathways

Contact Info

Product

Resources

About